Literature DB >> 29353031

Uterine preservation vs hysterectomy in pelvic organ prolapse surgery: a systematic review with meta-analysis and clinical practice guidelines.

Kate V Meriwether1, Danielle D Antosh2, Cedric K Olivera3, Shunaha Kim-Fine4, Ethan M Balk5, Miles Murphy6, Cara L Grimes7, Ambereen Sleemi8, Ruchira Singh9, Alexis A Dieter10, Catrina C Crisp11, David D Rahn12.   

Abstract

OBJECTIVE: We aimed to systematically review the literature on apical pelvic organ prolapse surgery with uterine preservation compared with prolapse surgeries including hysterectomy and provide evidence-based guidelines. DATA SOURCES: The sources for our data were MEDLINE, Cochrane, and clinicaltrials.gov databases from inception to January 2017. STUDY ELIGIBILITY CRITERIA: We accepted randomized and nonrandomized studies of uterine-preserving prolapse surgeries compared with those involving hysterectomy. STUDY APPRAISAL AND SYNTHESIS
METHODS: Studies were extracted for participant information, intervention, comparator, efficacy outcomes, and adverse events, and they were individually and collectively assessed for methodological quality. If 3 or more studies compared the same surgeries and reported the same outcome, a meta-analysis was performed.
RESULTS: We screened 4467 abstracts and identified 94 eligible studies, 53 comparing uterine preservation to hysterectomy in prolapse surgery. Evidence was of moderate quality overall. Compared with hysterectomy plus mesh sacrocolpopexy, uterine preservation with sacrohysteropexy reduces mesh exposure, operative time, blood loss, and surgical cost without differences in prolapse recurrence. Compared with vaginal hysterectomy with uterosacral suspension, uterine preservation in the form of laparoscopic sacrohysteropexy improves the C point and vaginal length on the pelvic organ prolapse quantification exam, estimated blood loss, postoperative pain and functioning, and hospital stay, but open abdominal sacrohysteropexy worsens bothersome urinary symptoms, operative time, and quality of life. Transvaginal mesh hysteropexy (vs with hysterectomy) decreases mesh exposure, reoperation for mesh exposure, postoperative bleeding, and estimated blood loss and improves posterior pelvic organ prolapse quantification measurement. Transvaginal uterosacral or sacrospinous hysteropexy or the Manchester procedure compared with vaginal hysterectomy with native tissue suspension both showed improved operative time and estimated blood loss and no worsening of prolapse outcomes with uterine preservation. However, there is a significant lack of data on prolapse outcomes >3 years after surgery, the role of uterine preservation in obliterative procedures, and longer-term risk of uterine pathology after uterine preservation.
CONCLUSION: Uterine-preserving prolapse surgeries improve operating time, blood loss, and risk of mesh exposure compared with similar surgical routes with concomitant hysterectomy and do not significantly change short-term prolapse outcomes. Surgeons may offer uterine preservation as an option to appropriate women who desire this choice during apical prolapse repair.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  hysteropexy; pelvic organ prolapse; surgery; transvaginal mesh; uterine preservation

Mesh:

Year:  2018        PMID: 29353031     DOI: 10.1016/j.ajog.2018.01.018

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  31 in total

1.  Uterine-preserving surgeries for the repair of pelvic organ prolapse: a systematic review with meta-analysis and clinical practice guidelines.

Authors:  Kate V Meriwether; Ethan M Balk; Danielle D Antosh; Cedric K Olivera; Shunaha Kim-Fine; Miles Murphy; Cara L Grimes; Ambereen Sleemi; Ruchira Singh; Alexis A Dieter; Catrina C Crisp; David D Rahn
Journal:  Int Urogynecol J       Date:  2019-02-11       Impact factor: 2.894

2.  Teaching learners to raise the roof: a vaginal surgery simulator for apical suspension.

Authors:  Cassandra K Kisby; Mary V Baker; Isabel C Green; John A Occhino
Journal:  Int Urogynecol J       Date:  2019-06-06       Impact factor: 2.894

3.  Commentary on 'Surgical treatment of primary uterine prolapse: a comparison of vaginal native tissue surgical techniques'.

Authors:  Matthew L Izett
Journal:  Int Urogynecol J       Date:  2019-05-23       Impact factor: 2.894

4.  Back to the future: vaginal hysterectomy and Campbell uterosacral ligaments suspension for urogenital prolapse.

Authors:  Caroline Pettenati; Florence Cour; Pierre-Olivier Bosset; Titouan Kennel; Adrien Vidart; Thierry Lebret
Journal:  Int Urogynecol J       Date:  2021-02-23       Impact factor: 2.894

5.  How do patients and surgeons decide on uterine preservation or hysterectomy in apical prolapse?

Authors:  Breffini Anglim; Orfhlaith O'Sullivan; Barry O'Reilly
Journal:  Int Urogynecol J       Date:  2018-06-11       Impact factor: 2.894

6.  A comparison of modified laparoscopic uterine suspension and vaginal hysterectomy with sacrospinous ligament fixation for treating pelvic organ prolapse.

Authors:  Hongxia Zhu; Yixuan Sun; Xuan Zheng
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

7.  The resurrection of sacrospinous fixation: unilateral apical sling hysteropexy.

Authors:  Dmitry Shkarupa; Nikita Kubin; Ekaterina Shapovalova; Anastasya Zaytseva
Journal:  Int Urogynecol J       Date:  2019-06-10       Impact factor: 2.894

Review 8.  Prolapse Repair Using Non-synthetic Material: What is the Current Standard?

Authors:  Ricardo Palmerola; Nirit Rosenblum
Journal:  Curr Urol Rep       Date:  2019-10-14       Impact factor: 3.092

9.  Joint report on terminology for surgical procedures to treat pelvic organ prolapse.

Authors: 
Journal:  Int Urogynecol J       Date:  2020-03       Impact factor: 2.894

10.  Hysterectomy with uterosacral suspension or Uphold™ hysteropexy in women with apical prolapse: a parallel cohort study.

Authors:  Mugdha Kulkarni; Natharnia Young; Joseph Lee; Anna Rosamilia
Journal:  Int Urogynecol J       Date:  2020-05-28       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.